+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cancer Gene Therapy Market Research Report by Therapy (Gene Induced Immunotherapy, Gene Transfer, and Oncolytic Virotherapy), End-Use, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • PDF Icon

    Report

  • 249 Pages
  • January 2023
  • Region: Global
  • 360iResearch™
  • ID: 5715913
UP TO OFF until Mar 31st 2023
The Global Cancer Gene Therapy Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation. Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the Global Cancer Gene Therapy Market.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Cancer Gene Therapy Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Cancer Gene Therapy Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Cancer Gene Therapy Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Cancer Gene Therapy Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for the market plan. This research report categorizes the Global Cancer Gene Therapy Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Therapy, the market is studied across Gene Induced Immunotherapy, Gene Transfer, and Oncolytic Virotherapy.
  • Based on End-Use, the market is studied across Biopharmaceutical Companies, Diagnostic Centers, and Research Institutes.
  • Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Cancer Gene Therapy Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Cancer Gene Therapy Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Cancer Gene Therapy Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Cancer Gene Therapy Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Gene Therapy Market, including .

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer Gene Therapy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Gene Therapy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Gene Therapy Market?
4. What is the competitive strategic window for opportunities in the Global Cancer Gene Therapy Market?
5. What are the technology trends and regulatory frameworks in the Global Cancer Gene Therapy Market?
6. What is the market share of the leading vendors in the Global Cancer Gene Therapy Market?
7. What modes and strategic moves are considered suitable for entering the Global Cancer Gene Therapy Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Cancer Gene Therapy Market, by Therapy
6.1. Introduction
6.2. Gene Induced Immunotherapy
6.3. Gene Transfer
6.4. Oncolytic Virotherapy

7. Cancer Gene Therapy Market, by End-Use
7.1. Introduction
7.2. Biopharmaceutical Companies
7.3. Diagnostic Centers
7.4. Research Institutes

8. Americas Cancer Gene Therapy Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Cancer Gene Therapy Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Cancer Gene Therapy Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Product Portfolio Analysis, By Key Player
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL CANCER GENE THERAPY MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER GENE THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER GENE THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL CANCER GENE THERAPY MARKET DYNAMICS
FIGURE 11. GLOBAL CANCER GENE THERAPY MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2022 VS 2030 (%)
FIGURE 13. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL CANCER GENE THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY THERAPY, 2030
FIGURE 15. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GENE INDUCED IMMUNOTHERAPY, 2018-2030 (USD MILLION)
FIGURE 16. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GENE TRANSFER, 2018-2030 (USD MILLION)
FIGURE 17. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, 2018-2030 (USD MILLION)
FIGURE 18. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2022 VS 2030 (%)
FIGURE 19. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL CANCER GENE THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY END-USE, 2030
FIGURE 21. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
FIGURE 22. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
FIGURE 23. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
FIGURE 24. AMERICAS CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 25. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 26. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 27. AMERICAS CANCER GENE THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 28. ARGENTINA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 29. BRAZIL CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 30. CANADA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 31. MEXICO CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 32. UNITED STATES CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 33. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 34. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 35. UNITED STATES CANCER GENE THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 36. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 37. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 38. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 39. ASIA-PACIFIC CANCER GENE THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 40. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 41. CHINA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 42. INDIA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 43. INDONESIA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 44. JAPAN CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 45. MALAYSIA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 46. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 47. SINGAPORE CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 48. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 49. TAIWAN CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 50. THAILAND CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 51. VIETNAM CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 52. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 53. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 54. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 55. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 56. DENMARK CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 57. EGYPT CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 58. FINLAND CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 59. FRANCE CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 60. GERMANY CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 61. ISRAEL CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 62. ITALY CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 63. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 64. NIGERIA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 65. NORWAY CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 66. POLAND CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 67. QATAR CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 68. RUSSIA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 69. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 70. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 71. SPAIN CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 72. SWEDEN CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 73. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 74. TURKEY CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 75. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 76. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 77. GLOBAL CANCER GENE THERAPY MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 78. GLOBAL CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 79. GLOBAL CANCER GENE THERAPY MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. GLOBAL CANCER GENE THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GENE INDUCED IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GENE INDUCED IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GENE INDUCED IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GENE TRANSFER, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GENE TRANSFER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GENE TRANSFER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 36. CANADA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 37. CANADA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 38. CANADA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 39. MEXICO CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 40. MEXICO CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 41. MEXICO CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 50. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 51. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 52. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 53. CHINA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 54. CHINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 55. CHINA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 56. INDIA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 57. INDIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 58. INDIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 59. INDONESIA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 60. INDONESIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 61. INDONESIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 62. JAPAN CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 63. JAPAN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 64. JAPAN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 65. MALAYSIA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 66. MALAYSIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 67. MALAYSIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 68. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 69. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 70. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 71. SINGAPORE CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 72. SINGAPORE CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 73. SINGAPORE CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 74. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 75. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 76. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 77. TAIWAN CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 78. TAIWAN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 79. TAIWAN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 80. THAILAND CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 81. THAILAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 82. THAILAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 83. VIETNAM CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 84. VIETNAM CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 85. VIETNAM CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 90. DENMARK CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 91. DENMARK CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 92. DENMARK CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 93. EGYPT CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 94. EGYPT CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 95. EGYPT CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 96. FINLAND CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 97. FINLAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 98. FINLAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 99. FRANCE CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 100. FRANCE CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 101. FRANCE CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 102. GERMANY CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 103. GERMANY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 104. GERMANY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 105. ISRAEL CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 106. ISRAEL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 107. ISRAEL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 108. ITALY CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 109. ITALY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 110. ITALY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 111. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 112. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 113. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 114. NIGERIA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 115. NIGERIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 116. NIGERIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 117. NORWAY CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 118. NORWAY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 119. NORWAY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 120. POLAND CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 121. POLAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 122. POLAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 123. QATAR CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 124. QATAR CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 125. QATAR CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 129. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 130. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 131. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 132. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 133. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 134. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 135. SPAIN CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 136. SPAIN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 137. SPAIN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 138. SWEDEN CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 139. SWEDEN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 140. SWEDEN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 141. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 142. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 143. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 144. TURKEY CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 145. TURKEY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 146. TURKEY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 153. GLOBAL CANCER GENE THERAPY MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 154. GLOBAL CANCER GENE THERAPY MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 155. GLOBAL CANCER GENE THERAPY MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 156. GLOBAL CANCER GENE THERAPY MARKET RANKING, BY KEY PLAYER, 2022
TABLE 157. GLOBAL CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2022
TABLE 158. GLOBAL CANCER GENE THERAPY MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 159. GLOBAL CANCER GENE THERAPY MARKET MERGER & ACQUISITION
TABLE 160. GLOBAL CANCER GENE THERAPY MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 161. GLOBAL CANCER GENE THERAPY MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 162. GLOBAL CANCER GENE THERAPY MARKET INVESTMENT & FUNDING
TABLE 163. GLOBAL CANCER GENE THERAPY MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 164. GLOBAL CANCER GENE THERAPY MARKET: LICENSE & PRICING

Methodology

Loading
LOADING...